4//SEC Filing
Ciaramella Giuseppe 4
Accession 0000950170-24-041426
CIK 0001745999other
Filed
Apr 2, 8:00 PM ET
Accepted
Apr 3, 7:33 PM ET
Size
10.4 KB
Accession
0000950170-24-041426
Insider Transaction Report
Form 4
Ciaramella Giuseppe
President
Transactions
- Sale
Common Stock
2024-04-01$32.12/sh−4,534$145,632→ 169,616 total - Award
Stock Option (Right to Buy)
2024-04-03+27,318→ 27,318 totalExercise: $0.67From: 2024-04-03Exp: 2028-05-08→ Common Stock (27,318 underlying) - Award
Stock Option (Right to Buy)
2024-04-03+12,979→ 12,979 totalExercise: $4.22From: 2024-04-03Exp: 2029-02-13→ Common Stock (12,979 underlying)
Footnotes (4)
- [F1]These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on each of March 31, 2021, March 31, 2022 and March 31, 2023. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $32.09 to $32.18, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]On May 8, 2018, the Reporting Person was granted an option to purchase 27,318 shares of common stock of BEAM. The option vests upon BEAM achieving a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 27,318 shares.
- [F4]On February 13, 2019, the Reporting Person was granted an option to purchase 12,979 shares of common stock of BEAM. The option vests upon BEAM achieving a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 12,979 shares.
Documents
Issuer
Beam Therapeutics Inc.
CIK 0001745999
Entity typeother
Related Parties
1- filerCIK 0001786322
Filing Metadata
- Form type
- 4
- Filed
- Apr 2, 8:00 PM ET
- Accepted
- Apr 3, 7:33 PM ET
- Size
- 10.4 KB